Compare Globus Medical Inc. Class A Common Stock (GMED) vs Lululemon Athletica Inc (LULU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Lululemon Athletica Inc — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Lululemon Athletica Inc trades at $93.58 (market cap $10.44B). The key difference: Globus Medical Inc. Class A Common Stock and Lululemon Athletica Inc are close in size by market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, Lululemon Athletica Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Lululemon Athletica Inc for 106 Days on average.
| GMED | LULU | |
|---|---|---|
Market Cap | $10.25B | $10.44B |
Volume | 1,108,124 | 2,759,135 |
Sector | Health | Consumer Cyclical |
52-Week High | $96.82 | $215.88 |
52-Week Low | $58.33 | $91.88 |
Typical Hold Time | 0 Days | 106 Days |
Enterprise Value | $9.76B | $11.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Lululemon stock trades at $94.09, down 54% year-to-date and near its 52-week low. The technical picture is bearish with resistance at $96 and support at $93. Fundamentally, the company reported strong revenue of $10.59B in 2025 and a net income margin of 12.78%, but faces growth concerns. Recent news highlights a securities fraud investigation and competitive pressures in athletic apparel.
The outlook is cautious due to legal overhangs and weakening sentiment, though valuation ratios like a P/E of 7.76 appear attractive. Risks include governance turmoil and consumer shifts. Analyst consensus is a $97.67 price target with a mixed buy/hold rating split, suggesting potential recovery if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Lululemon Athletica Inc
Lululemon Athletica Inc. designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. Lululemon offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. The company also sells fitness accessories, such as bags, yoga mats, and equipment. Lululemon sells its products through more than 600 company-owned stores in 18 countries, e-commerce, outlets, and wholesale accounts. The company was founded in 1998 and is based in Vancouver, Canada.
Read more on LULU →
